Wnt, notch, and TGF-β pathways impinge on hedgehog signaling complexity: an open window on cancer by Pelullo, Maria et al.
1 August 2019 | Volume 10 | Article 711
REVIEW
doi: 10.3389/fgene.2019.00711
published: 21 August 2019
Frontiers in Genetics | www.frontiersin.org
Edited by: 
William Cho, 
Queen Elizabeth Hospital (QEH), 
Hong Kong
Reviewed by: 
Bradley Doble, 
McMaster University, Canada 
Paola Rizzo, 
University of Ferrara, Italy
*Correspondence: 
Maria Pelullo 
Maria.Pelullo@iit.it 
Diana Bellavia 
diana.bellavia@uniroma1.it
Specialty section: 
This article was submitted to 
Stem Cell Research, 
a section of the journal 
Frontiers in Genetics
Received: 13 March 2019
Accepted: 05 July 2019
Published: 21 August 2019
Citation: 
Pelullo M, Zema S, Nardozza F, 
Checquolo S, Screpanti I and 
Bellavia D (2019) Wnt, Notch, 
and TGF-β Pathways Impinge on 
Hedgehog Signaling Complexity: An 
Open Window on Cancer. 
Front. Genet. 10:711. 
doi: 10.3389/fgene.2019.00711
Wnt, Notch, and TGF-β Pathways 
Impinge on Hedgehog Signaling 
Complexity: An Open Window on 
Cancer
Maria Pelullo 1*, Sabrina Zema 2, Francesca Nardozza 2, Saula Checquolo 3, 
Isabella Screpanti 2 and Diana Bellavia 2*
1 Center of Life Nano Science Sapienza, Istituto Italiano di Tecnologia, Rome, Italy, 2 Department of Molecular Medicine, Sapienza 
University, Rome, Italy, 3 Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy
Constitutive activation of the Hedgehog (Hh) signaling pathway is associated with increased 
risk of developing several malignancies. The biological and pathogenic importance 
of Hh signaling emphasizes the need to control its action tightly, both physiologically 
and therapeutically. Evidence of crosstalk between Hh and other signaling pathways is 
reported in many tumor types. Here, we provide an overview of the current knowledge 
about the communication between Hh and major signaling pathways, such as Notch, 
Wnt, and transforming growth factor β (TGF-β), which play critical roles in both embryonic 
and adult life. When these pathways are unbalanced, impaired crosstalk contributes to 
disease development. It is reported that more than one of these pathways are active in 
different type of tumors, at the same time. Therefore, starting from a plethora of stimuli that 
activate multiple signaling pathways, we describe the signals that preferentially converge 
on the Hh signaling cascade that influence its activity. Moreover, we highlight several 
connection points between Hh and Notch, Wnt, or TGF-β pathways, showing a reciprocal 
synergism that contributes to tumorigenesis, supporting a more malignant behavior by 
tumor cells, such as in leukemia and brain tumors. Understanding the importance of 
these molecular interlinking networks will provide a rational basis for combined anticancer 
drug development.
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INTRODUCTION
Signaling pathways are networks of regulatory proteins and other gene products that act in a 
coordinated manner to control various biological processes inside the cell. Remarkably, mutation of 
a single gene encoding a component of a specific pathway is able to affect related signaling cascades, 
triggering unbalanced crosstalk that leads to cancer development. Of note, impaired regulation of 
primary signaling pathways can ultimately culminate in constitutive activation of signaling effectors 
in the nucleus, where they act out of control, sustaining the expression of pro-tumoral target genes. 
To date, it is known that tumor development is characterized by deregulation of at least two major 
signaling pathways at the same time, which crosstalk with each other, determining the acquisition 
of malignant phenotypes (Petrova and Joyner, 2014).
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Hedgehog (Hh) signaling is a critical pathway that mainly 
controls embryonic development, whereas in post-natal life, it 
is inactive or poorly active, playing a restricted role in stem cell 
maintenance and tissue homeostasis/repair (Petrova and Joyner, 
2014). Since Hh signaling regulates a wide array of biological 
activities in various cell types, its misregulation is responsible 
for the development of many types of cancers. Studies show 
that the mutational activation of Hh signaling is a nodal point 
in sustaining tumorigenic programs, ranging from the tumor 
initiation to tissue invasion/metastasis and chemoresistance, in 
several different tumors.
Of note, recent studies show that Hh signaling elements talk 
to several other cofactors belonging to major pathways, such as 
Notch, Wnt, and transforming growth factor β (TGF-β), resulting 
in significant crosstalk between these signaling networks. The 
integration of several signaling pathways is a key step able 
to determine a more aggressive behavior of tumor cells and 
their resistance to pharmacological approaches. Interestingly, 
Notch, Wnt, and TGF-β pathways are able to promote/sustain 
oncogenesis through synergistic associations with Hh signaling 
in several types of tumors.
Here, we review a global picture of intricate protein–protein 
interaction networks between key components of Hedgehog, Wnt, 
Notch, and TGF-β signaling pathways in an unbalanced/malignant 
context. We also describe how these main pathways can integrate 
with each other and ultimately affect Hh signaling output.
THE HEDGEHOG PATHWAY
First discovered in Drosophila, Hedgehog signaling is an 
evolutionarily conserved pathway that plays a key role as a 
morphogenesis driver for embryonic and post-natal development. 
It regulates diverse cellular processes, including cell proliferation, 
tissue differentiation, and repair of normal tissues (Nusslein-
Volhard and Wieschaus, 1980; Napolitano et al., 1999; Varjosalo 
and Taipale, 2008), and it is also implicated in regulation/survival 
of normal and malignant stem cells (Liu et al., 2006; Merchant 
and Matsui, 2010). Canonical Hedgehog pathway activation 
is characterized by the interaction of Hh ligands, Sonic (SHh), 
Indian (IHh), and Desert (DHh), to the Patched1 (Ptch1) 
receptor, which resides in the primary cilium (PC) (Rohatgi 
et  al., 2007; Wong and Reiter, 2008). Interestingly, the PC is a 
key organelle that consists of microtubules emanating from the 
cell surface in which SHh signaling takes place, and it responds 
to mechanical stimuli in the micro-environment (Michaud and 
Yoder, 2006). In the absence of Hh ligand, Ptch localizes to the 
base of the PC and catalytically represses the activity of the 
transducer Smoothened (SMO) (Burns et al., 2018), a member 
of G-protein–coupled receptor-like (GPCR), by inhibiting 
its translocation into the PC (Denef et al., 2000) (Figure 1A). 
SMO is a seven-transmembrane-span receptor-like protein 
that is confined to intracellular endocytic vesicles when the Hh 
pathway is switched off (Taipale et al., 2002). Hh binding both 
causes the internalization of ligand/receptor complex from the 
cell surface towards lysosomes, where the proteins are degraded 
(Mastronardi et al., 2000), and promotes the accumulation of 
SMO at the cell surface (Denef et al., 2000). Once activated, SMO 
is hyperphosphorylated by casein kinase 1 (CK1) and G-protein–
coupled receptor kinase 2 (GRK2), resulting in the release of its 
inhibition, and at this point, it is free to move from the base into 
the tip of the PC (Denef et al., 2000; Chen et al., 2011) (Figure 1B). 
Given these features, SMO is considered a positive regulator 
of the Hh signaling pathway because, when it is constitutively 
activated, it stimulates downstream components of the signaling 
pathway. Therefore, the ligand/receptor complex relieves the SMO 
FIGURE 1 | Canonical Hh signaling. The canonical Hh signaling pathway in off (panel A) or on (panel B) state. The figure is widely discussed in the text. The red dots 
represent post-translational modifications: phosphorylation.
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inhibition and triggers a cascade of intracellular processes that 
involve a dynamic association between Gli transcription factors, 
the final effectors of Hh signaling, and Suppressor of Fused 
(SuFu). Unlike SMO, SuFu is considered a tumor suppressor 
gene and a negative regulator of Hedgehog signaling, able to bind 
directly to Gli proteins to regulate their activity, processing, and 
localization, (Ryan and Chiang, 2012), by sequestering them in 
the cytosol (Ding et al., 1999; Dunaeva et al., 2003) or regulating 
their affinity to DNA (Pearse et al., 1999; Stone et al., 1999; Sisson 
et al., 2006). However, the specific mechanisms concerning Gli 
inactivation by SuFu are not completely understood (Carballo 
et al., 2018). Hh ligand binding sustains the release of Gli 
from SuFu that moves into the nucleus and activates Hh target 
genes. Altogether, these molecular events sustain the signal 
that is transduced from the ligand/receptor complex to the 
downstream transcription factors (Gli1, Gli2, and Gli3), which 
in turn translocate into the nucleus and regulate the expression 
of Hh target genes, including Gli1 itself. Prominently, Gli1 is 
both the downstream effector and a target gene of the pathway, 
representing a feedback loop that serves as a readout of Hh activity 
(Sasaki et al., 1999; Regl et al., 2002). Interestingly, Gli1 consists 
of zinc finger and C-terminal activator domains, whereas Gli2 
and Gli3 also possess an N-terminal repressor domain. On the 
basis of these structural differences, Gli1 functions exclusively 
as a transcriptional activator, whereas Gli2 and Gli3 exist as 
full-length (FL) activator and truncated repressor (GliR) forms, 
displaying in this way both positive and negative transcriptional 
functions (Lee et al., 1997; Dai et al., 1999; Sasaki et al., 1999; Bai 
et al., 2004). In the absence of Hh ligand, GliFL is phosphorylated 
by protein kinase-A (PKA), glycogen synthase kinase-3 (GSK3), 
and CK1 (Price and Kalderon, 2002), and recognized by 
β-transducin-repeat containing protein (β-TrCP), which is able 
to partially degrade Gli proteins in truncated forms (Glis). At 
this point, Gli proteins retained at the cytoplasm by SuFu are 
degraded, inhibiting SHh signaling (Humke et al., 2010). These 
events lead to proteolytic cleavage of GliFL into C-terminally 
truncated repressor form, GliR, which translocates to the 
nucleus, where it binds to Hh target gene promoters and keeps 
them switched off (Goetz and Anderson, 2010). Interestingly, 
a recent paper shows that the Itch/β-arrestin2 complex binds 
SuFu and induces its polyubiquitination without any impact on 
stability, but sustaining the conversion of Gli3 into a repressor, 
which is able to switch off the signal (Infante et al., 2018).
Under basal conditions, Gli1 activity can be controlled by 
proteasome degradation, mediated by two distinct ubiquitin-
dependent processing pathway E3 ubiquitin ligases, β-TrCP 
and Itch, able to inactive Gli1 in the cytosol (Lee et al., 1997; Di 
Marcotullio et al., 2006; Di Marcotullio et al., 2007; Di Marcotullio 
et al., 2011; Infante et al., 2016). On the contrary, the activation of 
Hh/Gli signaling is associated with a translocation of Gli1 into the 
nucleus, where it exerts strong mitogenic and prosurvival activities. 
Another mechanism able to control the Hh signaling is based on the 
acetylation status of Gli1 and Gli2, mediated by Histone deacetylases 
(HDACs). Indeed, HDAC-mediated deacetylation promotes 
transcriptional activation and sustains a positive regulatory loop. 
This mechanism is turned off by HDAC1 degradation, mediated by 
a Cullin3/Ren complex (Canettieri et al., 2010).
Recent studies identify Mastermind-like 1 (Maml1) as a novel 
positive regulator of Hh signaling. It physically interacts with 
Gli proteins (Gli1 and Gli2), working as a potent transcriptional 
coactivator (Quaranta et al., 2017; Vied and Kalderon, 2009), 
empowering Gli-mediated transcriptional activity. Finally, Gli1 
activation induces the transcription of Hh target genes involved 
in key cellular processes, such as the cell cycle (Cyclin D1 and 
D2) (Sasaki et al., 1999), apoptosis (Bcl2) (Bigelow et al., 2004), 
N-Myc (Oliver et al., 2003), various transcription factors and 
components of the Hh pathway itself such as Ptch1, Ptch2, 
and Gli1 for negative and positive feedback loop mechanisms 
(canonical target genes) (Bonifas et al., 2001; Oliver et al., 2003, 
Vokes et al., 2007; Coni et al., 2013), and elements of other 
pathways such as Notch1 and Jagged1 (Stecca and Ruiz i Altaba, 
2009), Hes1 (Ingram et al., 2008; Wall et al., 2009), Wnt signals 
(Mullor et al., 2001), and TGF-β members (Fan et al., 2010) 
(non-canonical target genes), suggesting that the Hh signaling 
pathway can integrate with elements of major signaling pathways 
(Figure 1).
HEDGEHOG MUTATIONS AND DISEASE
Mutational activation of the Hh signaling pathway is tightly linked 
to maintenance of tumor-initiating stem cells, tumorigenesis, and 
tumor invasiveness in several types of cancer (Nilsson et al., 2000; 
Varnat et al., 2009; Harris et al., 2012). Mutations in Hh signaling 
can be classified as loss of function (i.e., Ptch1 and SuFu) or gain of 
function (i.e., Gli1, Gli2, and SMO), both associated with an aberrant 
activation of the Hh pathway (Table 1). Constitutive Hh signaling 
triggers a strong cellular mitogenic response that ultimately 
predisposes to abnormal proliferation leading to tumorigenesis.
Notably, it is known that patients with Gorlin syndrome 
(GS), also called nevoid basal cell carcinoma syndrome (nevoid 
BCC) or basal cell nevus syndrome, are predisposed to multiple 
cancers, including basal cell carcinoma (BCC), medulloblastoma 
(MB), and rhabdomyosarcoma (Johnson et al., 1996; Jones et al., 
2011). Gorlin syndrome patients carry mutations in Ptch1 and 
SuFu genes (Hahn et al., 1996; Smith et al., 2014). Of note, SuFu 
germline mutations are present with a low frequency (Smith et al., 
2014). By contrast, heterozygous germline mutations in Ptch1, 
including nonsense, missense, splicing mutations, as well as loss of 
heterozygosity (LOH) (Burns et al., 2018), are typical alterations in 
these patients, inducing different tumors (Lindstrom et al., 2006). 
In patients with GS, the loss of function of the Ptch1 gene permits 
SMO to move into the PC, resulting in an aberrant activation 
of Hh signaling, which drives cellular growth of these tumors. 
Notably, the Ptch1 knock-out mouse model develops tumors 
similar to Gorlin syndrome patients, like BCC, MBs, and sporadic 
rhabdomyosarcomas, providing evidence about the driver role of 
Hh signaling for cancer development (Hahn et al., 1996; Nitzki 
et al., 2011). The co-presence of Ptch1 and SuFu mutations or Gli1 
amplifications is also identified in rhabdomyosarcoma patients 
(Bridge et al., 2000; Roberts et al., 1989). Finally, combined 
heterozygous Ptch1 and Ptch2 germline mutations are observed 
in newborns with rhabdomyosarcoma (Taeubner et al., 2018), 
suggesting that haploinsufficiency of Ptch is sufficient to sustain 
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tumor development in the absence of LOH (Nilsson et al., 2000). 
In addition, MB is one the most common brain tumors affecting 
mostly children and is a typical GS-related cancer (Jones et al., 
2011; Huttner, 2012). GS patients characterized by SuFu mutations 
display a higher risk of developing MB than Ptch1-mutated 
patients. Based on the molecular features that are involved 
in MB pathogenesis, it is possible to distinguish four groups: 
SHh-activated, WNT-activated, c-Myc–activated, and Group 4 
associated with isochromosome 17q (Kool et al., 2012; Rusert 
et al., 2014). In MB, Hh-dependent tumorigenesis may depend 
on an aberrant regulation of Hh ligands or a deregulation of Hh 
signaling with an altered expression/function of downstream 
components, such as loss-of-function mutations of Ptch1 or 
SUFU (Taylor et al., 2002; Kool et al., 2012) or, conversely, 
activating mutations of SMO and SHh (Reifenberger et al., 1998; 
Zurawel et al., 2000). Of note, somatic copy number variations 
of Gli1 and Gli2 genes are found in this subgroup (Thompson 
et al., 2006; Northcott et al., 2009). All these mutations allow 
ligand-independent Hh signaling to promote cell growth and 
increase tumorigenesis.
Alterations in Hh signaling are also described in 
meningiomas, the most common primary tumor of the central 
nervous system (Wiemels et al., 2010). Aavikko and colleagues 
identified a germline SuFu mutation as the cause of multiple 
meningiomas in a single large Finnish family, suggesting that 
SuFu alterations predispose to meningiomas in addition to MBs 
(Aavikko et al., 2012).
BCC is a common type of skin cancer, representing almost 
80% of non-melanoma skin cancer (NMSC), with an incidence 
that increases by 10% per year (Bakshi et al., 2017). As argued 
above, BCC is linked to GS and is characterized by germline 
mutations of Ptch1 and SuFu. Accordingly, sporadic BCC presents 
hyperactivated Hh signaling, associated with inactivating 
mutations in Ptch1 and activating mutations in SMO, with a 
high-rate frequency (Gailani et al., 1996; Reifenberger et  al., 
1998; Xie et al., 1998). Moreover, loss of SuFu function is also 
found in sporadic BCC (Reifenberger et al., 2005). Couvè-Privat 
and colleagues identify the presence of ultraviolet (UV)-specific 
mutations in the NH2-terminal domain of SHh in BCC patients 
with xeroderma pigmentosum (Couve-Privat et al., 2004). The 
current opinion is that during BCC genesis, SHh signaling 
aberrantly activated is necessary, maybe sufficient, to develop the 
malignancy (Teglund and Toftgard, 2010). In addition, there are 
numerous types of cancer associated with Hh signaling activation. 
Genetic aberrations on Hh signaling are found also in a subset of 
breast cancer, characterized by loss of function in Ptch1 and gain 
of function of Gli1 (Naylor et al., 2005; Nessling et al., 2005; Wood 
et al., 2007; Sinha et al., 2008; Jiao et al., 2012). A global genomic 
analysis from twenty-four advanced pancreatic adenocarcinomas 
highlighted the presence of missense mutations in Gli1 and Gli3 
(Jones et al., 2008), and Hh signaling pathway is recognized as 
an early and late mediator of pancreatic cancer tumorigenesis 
(Thayer et al., 2003). Also, in prostate cancer is identified a SuFu 
mutation (Sheng et al., 2004). Recently, in patients with T-cell 
acute lymphoblastic leukemia (T-ALL), several mutations of 
SHh signaling are described (Dagklis et al., 2016), and loss 
of Ptch1 function is able to empower T-ALL development 
Notch1-dependent, demonstrating that Hh pathway activation 
is an oncogenic driver in the molecular pathogenesis of T-ALL 
(Burns et al., 2018). In addition, SMO and Ptch1 mutations are 
also found in gastrointestinal tumors (Guleng et al., 2006; Wang 
et al., 2013). Lee and colleagues performed a single-strand 
conformation polymorphism analysis and DNA sequencing 
in samples of colorectal and gastric cancers and identified 
frameshift mutations of Gli1, associated with a microsatellite 
instability (MSI) phenotype. (Lee et al., 2018). Finally, SMO 
activating mutations are involved in ameloblastomas arising in 
the maxilla (Sweeney et al., 2014).
Although tumors not GS-related present direct mutations in 
genes involved in the Hh pathway, it is not possible to identify Hh 
signaling as the driving force for cancer onset. In fact, activated 
Hh signaling is able to empower the severity of the tumors, but 
this pathway alone is not capable of driving cancer development. 
A major elucidation of the mechanisms leading to the genesis of 
malignancy through an aberrant activation of this pathway and/
or unbalanced cross-talking with other signaling pathways could 
provide additional therapeutic options to limit tumor growth 
and relapse and to reduce drug resistance.
COMMUNICATION AMONG HH AND 
DIFFERENT SIGNALING PATHWAYS
Crosstalk Between Hh and Notch 
Signaling Pathways
The family of Notch receptors includes four heterodimeric 
transmembrane proteins (Notch1–4), which are activated upon 
interaction with different types of ligands [Serrate-like Jagged1 
and 2 (JAG1–2) and Delta-like (Delta1, 3, and 4)], expressed 
by adjacent cells. The activation of Notch signaling requires 
the binding in trans between Notch receptors, expressed 
on the surface of signal-receiving cells, and Notch ligands, 
expressed on the surface of adjacent signal-sending cells. Such 
an interaction renders Notch susceptible to two sequential 
proteolytic cleavages that involve two distinct enzymes: an 
A-disintegrin and metalloprotease (ADAM) and Presenilin 
(PS)/γ-secretase complex. These events end in the release of a 
soluble Notch intracellular domain (NICD) (Mumm and Kopan, 
2000; Fortini,  2009; Kopan and Ilagan, 2009; Palermo et al., 
2014; Bellavia et al., 2018). In canonical Notch signaling, NICD 
disengages from the plasma membrane and proceeds towards the 
nucleus, where it associates with recombining binding protein 
suppressor of hairless J kappa (RBP-Jκ, also known as RBPSUH/
CSL/CBF-1), a transcription repressor. CSL–NICD complex, 
reached by a member of Mastermind-family coactivators 
(MAML1–3) (Wu et al., 2000), induces the transcriptional 
activation of several target genes, for instance, HES1/5, HEY 
(Bellavia et al., 2018), Myc (Palomero et al., 2006; Weng et al., 
2006), cyclinD (Joshi et  al., 2009; Cohen et al., 2010), pTalpha 
(Bellavia et al., 2007b), and Jagged1 (Pelullo et al., 2014). Notch 
signaling activation also occurs in a non-canonical pathway. 
NICD can coactivate transcription by forming a complex with 
the lymphoid enhancer factor 1 (LEF-1) transcription factor 
(Ross and Kadesch, 2001) or by binding to p50 or c-Rel in 
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the nucleus to enhance the activity of the transcription factor 
NF-κB (Nuclear Factor-kappa B) (Shin et al., 2006; Vacca 
et  al., 2006; Kumar et al., 2014), and can modulate Tal-1 and/
or Ikaros activity (Beverly and Capobianco, 2003; Campese 
et al., 2003; Talora et al., 2006; Bellavia et al., 2007a; Talora et al., 
2008). Notch signaling, like the Hh pathway, is involved in the 
proliferation, differentiation, and survival of multiple tissues. 
In the hematopoietic system, Notch can increase the survival 
and self-renewal of hematopoietic progenitors (Varnum-Finney 
et al., 2000) and controls regulatory T-cell expansion/migration 
to peripheral lymphoid organs (Campese et al., 2009; Ferrandino 
et al., 2018a; Ferrandino et al., 2018b). Very intriguing is the 
observation that Notch1 and Notch3 receptors are associated 
with different steps of ongoing thymocyte development (Felli 
et al., 1999). This suggests that they work with distinct timing 
and with separate spatial expression, underlining the absence 
of a functional redundancy, an observation sustained also by 
structural differences (Bellavia et al., 2018). A hampered Notch 
signaling pathway takes place in several pathological events that 
range from neurodegenerative disorders to cancer (Joutel et al., 
2000). Persistent uncontrolled Notch signaling is responsible for 
the onset/progression of several tumors, such as T-cell leukemia 
(Checquolo et al., 2010; Cialfi et al., 2013; Vargas Romero 
et al., 2015; Franciosa et al., 2016; Tottone et  al., 2019), B-cell 
leukemia (Rosati et al., 2009; Arruga et al., 2014; De Falco et al., 
2015), breast cancer (Rustighi et al., 2014; Diluvio et al., 2018), 
colorectal (Reedijk et al., 2008; Sikandar et al., 2010), ovarian 
cancer (Choi et al., 2008; Steg et al., 2011; McAuliffe et al., 2012), 
glioma (Catanzaro et al., 2017; Ceccarelli et al., 2019), and skin 
cancer (Cialfi et al., 2014; Palermo et al., 2014). Numerous gain-
of-function mouse models show that mutations in Notch1/3 
signaling are related to rare cases of human T-ALL (Bellavia et al., 
2000; Allman et al., 2001). Although first associated with T-ALL, 
activating Notch mutations are identified in several subtypes of 
B-cell malignancies (Micci et al., 2007; Rosati et al., 2009; Kuang 
et al., 2013; Radojcic and Maillard, 2014; De Falco et al., 2018).
Studies show that Notch and Hh signaling pathways share the 
exact spatio-temporal window during T-cell development even if 
they play a non-redundant role in orchestrating early thymocyte 
differentiation and proliferation before pre-T cell Receptor 
(pre- TCR) signal initiation (Crompton et al., 2007; Rowbotham 
et al., 2007; Drakopoulou et al., 2010). These findings suggest 
that Hh may synergize with Notch signaling to maintain an 
intracellular balance through a significant integration of these 
signaling pathways. It is known that aberrant Hh signaling 
contributes to tumor cell growth and survival and cancer stem cell 
(CSC) maintenance in lymphomas, leukemia, multiple myeloma, 
and B-cell chronic lymphocytic leukemia (CLL) (Dierks et al., 
2007; Lindemann, 2008; Singh et al., 2010; Decker et al., 2012; 
Aberger et al., 2017). To unravel the molecular mechanisms 
that subtend in the network of cross-talking pathways could be 
essential in treatment of hematological disease. Interestingly, 
Hh signaling is a potential therapeutic target for patients with 
myeloid and lymphoid leukemia, and Hh pathway inhibitors are 
used in many preclinical studies (Dagklis et al., 2016; Rimkus 
et al., 2016). Despite the importance of the Hh pathway in 
T-cell development and in several hematological malignancies 
(Mar et al., 2011), the role of the Hh pathway in T-ALL is 
unclear, and conflicting data are reported. A study shows that 
Hedgehog signaling is dispensable for T-ALL development (Gao 
et al., 2009), whereas other studies document T-ALL cell line 
sensitivity to Hh inhibitors, suggesting that this pathway may be 
important in T-ALL development and/or maintenance (Ji et al., 
2007; Hou et al., 2014; Dagklis et al., 2016). Recently, several 
reports highlight activating mutations in components of the Hh 
signaling in T-ALL, supporting the idea that Hedgehog pathway 
deregulation may play a role in the onset and/or development 
of T-ALL. Functional analysis confirms the gain-of-function 
properties of two truncated SMO mutations in T-ALL (Dagklis 
et al., 2015). Moreover, primary T-ALL cases with high Gli 
mRNA levels are sensitive to Hedgehog pathway inhibition by 
GANT61 or vismodegib in in vivo xenograft models (Hou et al., 
2014; Dagklis et al., 2016). Despite the numerous correlations, 
the existence of a direct molecular connection between Hh and 
Notch in T-ALL is not well documented, yet. Recently, it has 
been reported that loss of Ptch1 function is able to accelerate the 
onset of Notch1-induced human T-ALL, demonstrating that Hh 
pathway mutations are driver oncogenic alterations, providing a 
molecular rationale for targeted therapy (Burns et al., 2018).
On the contrary, a reciprocal exclusion between Hh and Notch 
signaling pathways is already defined in the skin. In particular, 
Notch1 deficiency results in an increased expression of Gli2, 
along with tumor development in squamous cell carcinoma 
(Okuyama et al., 2008).
Likewise, an inverted gradient between Hh and Notch is 
observed in normal colon crypt development (Kosinski et al., 2007; 
Takebe et al., 2011; Geissler and Zach, 2012). Very little is known 
regarding the crosstalk mechanisms between Hh and Notch in 
colorectal cancer (CRC) tumorigenesis and progression. A paper 
shows an antagonistic crosstalk between Hh and Notch in order to 
give rise to proper intestine organogenesis in the mouse, but the 
molecular mechanism is unknown (Kim et al., 2011). Moreover, 
interaction between Notch and Hedgehog signaling pathways is 
critical in regulating self-renewal, proliferation, and differentiation 
of target cells, ensuring correct organogenesis. Numerous evidence 
supports the significant role of Hh/Notch crosstalk in cancer 
biology and chemotherapy-resistant CSCs (Takebe et al., 2011). 
Studies suggest that crosstalk between Hh and Notch signaling 
pathways exists and may be involved in the regulation of embryonic 
stem cell fate determination (Huang et al., 2012), in self-renewal 
and differentiation of breast cancer cells (Guo et al., 2011), and 
in hepatic stellate cell fate (Xie et  al., 2013). In addition, a study 
provides evidence that Notch signaling regulates the expression of 
SHh in neuronal stem cells. Notch activation leads to expression of 
Hes3 and SHh through activation of serine/threonine protein kinase 
B (Akt), signal transducer and activator of transcription 3 (STAT3), 
and mammalian target of rapamycin (mTOR), which promote cell 
survival (Androutsellis-Theotokis et al., 2006). Conversely, Gli1 is 
able to sustain the transcription of Jagged1 and Notch1 in the brain 
(Stecca and Ruiz i Altaba, 2009), and Notch ligand Jagged2 (Katoh 
and Katoh, 2009). On the other hand, the Notch target Hes1, a 
repressive transcription factor, is able to suppress Hh signaling, by 
inhibiting Gli1 transcription in glioma and MB tumors (Schreck 
et al., 2010). Of note is the observation that Hes1, the principal effector 
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of the Notch pathway, is also a target of SHh in both in mesodermal 
and neural cells (Ingram et al., 2008). These data agree with the 
observation that in a subset of MB patients, Hes1 is upregulated 
and its expression correlates with shorter patient survival (Fan et al., 
2004). Combined activation of Hh and Notch signaling pathways is 
observed in prostate cancer cells (Domingo-Domenech et al., 2012) 
and in the pathogenesis of pituitary adenomas (Yavropoulou et al., 
2015). Furthermore, novel mechanistic insights demonstrate that 
Notch signaling plays a central role in left–right asymmetry, playing 
a crucial role in regulating cilium length (Krebs et al., 2003, Lopes 
et al., 2010). Interestingly, Notch signaling controls trafficking of Hh 
signaling mediators into the PC, sustaining the responsiveness to 
SHh (Kong et al., 2015, Stasiulewicz et al., 2015). Consistent with 
this observation, Notch and Presenilin 2, a subunit of the γ-secretase 
complex, localize around the PC. Notch signaling is activated by 
presenilin/γ-secretase activity, and the Notch intracellular domain 
is able to move into the nucleus to activate the transcription of 
several genes involved in cilium length and Hh signaling (Ezratty 
et al., 2011, Stasiulewicz et al., 2015). This phenomenon could be 
explained by the observation that the NICD/RBP-Jκ complex is 
able to drive the transcriptional activation of SMO and Gli2/3 in 
neuronal cells (Li et al., 2012) (Figure 2).
However, the existence of a regulatory mechanism impinging 
on the crosstalk between Hh and Notch in controlling tumor 
onset and progression needs to be better understood.
Crosstalk Between Hh and Wnt/β-Catenin 
Signaling Pathways
The Wnt family of secreted glycoproteins governs multiple 
developmental events during embryogenesis via the 
transcriptional coactivator β-catenin, and it is also implicated in 
adult tissue homeostasis and repair (Logan and Nusse, 2004).
In the absence of Wnt proteins, the cytoplasmic β-catenin protein 
is constantly degraded by the action of a β-catenin degradation 
complex, composed of the tumor suppressor adenomatous 
polyposis coli gene product (APC) (MacDonald et  al., 2009), 
the scaffolding protein Axin, CK1, and GSK3. Together, these 
proteins induce post-translational modifications, resulting in a 
phosphorylated β-catenin, which is recognized by β-TrCP, targeted 
for ubiquitination and degraded by the proteasome (He et al., 2004). 
Altogether, these events prevent a β-catenin shift into the nucleus, 
and Wnt/β-catenin target genes are thereby repressed by the 
T-cell factor (TCF)/LEF family of proteins (Brannon et al., 1997), 
FIGURE 2 | A schematic picture of the interlinking networks between Hh, Wnt/β-catenin, Notch, and TGF-β pathways inside a cancer cell. In the picture are 
represented the signals deriving from major signaling pathways that converge on the Hh signaling and vice versa. The figure is largely discussed in the main text. 
The black arrows represent the main signaling pathways; the dashed and truncated arrows indicate the positive and negative crosstalks between the pathways. The 
continuous and dashed rectangles contain canonical and non-canonical target genes, respectively.
Hh Signaling at a CrossroadPelullo et al.
7 August 2019 | Volume 10 | Article 711Frontiers in Genetics | www.frontiersin.org
associated with the transcriptional repressor Groucho/Transducin-
like enhancer protein (TLE) (Cavallo et al., 1998). The Wnt/β-catenin 
pathway is activated when a Wnt ligand binds to the seven-pass 
transmembrane Frizzled (Fz or Fzd) receptor, linked to (Brannon 
et al., 1997) its coreceptor, the low-density lipoprotein receptor-
related protein (LRP). Upon the employment of the scaffolding 
protein Dishevelled (Dvl), the Wnt–Fz–LRP complex induces the 
recruitment of the Axin complex to the receptors. These events 
lead to inhibition of Axin-mediated β-catenin phosphorylation 
and thereby to the stabilization of β-catenin, which accumulates 
and moves to the nucleus. Once there, β-catenin converts the TCF/
Groucho/TLE repressor complex into a transcriptional activator 
complex that activates the expression of Wnt target genes, such as 
Wnt components (MacDonald et al., 2009), c-Myc (He et al., 1998), 
Cyclin D1 (Tetsu and McCormick, 1999), and the Notch ligand 
Jagged1 (Rodilla et al., 2009) (Figure  2). Oncogenic mutations 
in canonical Wnt signaling determine a constitutive activation of 
the pathway in a ligand-independent manner, which is linked to 
human congenital disorders, cancers, and other diseases (Clevers, 
2006). Moreover, a recent review summarizes the wide range of 
epigenetic modifications of the Wnt signaling pathway that affects 
the development of a variety of tissues and organs, producing 
dramatic phenotypes and sustaining tumor formation (Wils and 
Bijlsma, 2018).
Recent studies show that Hh and Wnt signaling pathways 
can regulate each other, affecting their transcriptional output 
in specific cellular contexts in which they normally operate 
(Figure  2). Firstly, a crosstalk between Hh and Wnt signaling 
pathways is described to be involved in the onset/progression of 
BCC. In fact, aberrant Hh signaling activation, the key step in 
the tumorigenic program leading to BCC (Nilsson et al., 2000), 
determines the transcriptional activation of Wnt genes through 
Gli transcription factors (Bonifas et al., 2001; Katoh and Katoh, 
2009). Moreover, the existence of a positive feedback loop between 
Hh and Wnt is present during epithelial transformation, where 
Gli1 activates Snail, which in turn maintains Gli1 expression 
through Wnt/β-catenin signaling (Li et al., 2007).
Several reports demonstrate the existence of two-way 
communication between Hh and Wnt. On one hand, β-catenin 
is able to directly enhance the luciferase activity of Gli-responsive 
elements (Maeda et al., 2006) and to induce the post-transcriptional 
stabilization of Gli mRNAs, by upregulating CRD-BP, (coding 
region determinant-binding protein), an RNA-binding protein 
(Noubissi et al., 2009). On the other hand, Gli1 is able to induce 
the activation of Wnt2b, Wnt4, and Wnt7b, which in turn trigger 
Wnt/β-catenin signaling by promoting the stability of β-catenin 
itself (Li et al., 2007). In keeping with these experimental data, 
the inhibition of Hh signaling by cyclopamine reduces β-catenin/
TCF transcriptional activity, induces E-cadherin expression, and 
reduces invasion in CRC (Qualtrough et al., 2015). Moreover, 
inhibition of SHh signaling causes a reduction in Wnt-mediated 
transcriptional activity mediated by Gli3R, able to block the active 
form of the Wnt transcriptional effector, β-catenin, by physically 
interacting with the carboxy-terminal domain of β-catenin, a 
region that includes the transactivation domain (Ulloa et al., 2007).
Conversely, several data suggest an antagonism between 
Hh and WNT in CRC. In fact, a CRC cell line exposure to 
recombinant SHh results in the nuclear exit and membrane 
accumulation of β-catenin, consistent with its role in forming 
adherens junctions (Yoshimoto et al., 2012) and controlling 
epithelial–mesenchymal transition (EMT) (Varnat et al., 2010). 
In addition, it has been shown that Gli1/2 regulates the expression 
of secreted Frizzled-related protein sFRP-1 with a subsequent 
cytoplasmic accumulation of Wnt/β-catenin (He et al., 2006). 
All these data agree with a clinical study that demonstrated the 
reverse association of Gli1 and β-catenin in human samples 
of CRC. This study also showed that the overexpression of 
exogenous Gli1 determines a reduction of nuclear β-catenin in 
CRC cell lines (Akiyoshi et al., 2006).
Moreover, it reported that IHh, required for normal colonic 
epithelial differentiation (Ramalho-Santos et al., 2000), is also 
able to antagonize the proliferative Wnt signaling in crypts 
by abrogating endogenous β-catenin/TCF signaling (van 
den Brink et al., 2004). Consistently, an analysis of patients 
with APC mutations showed the loss of IHh expression in 
dysplastic epithelial cells present in adenomas, suggesting that 
IHh expression is downregulated in response to constitutive 
β-catenin/TCF signaling (Fu et al., 2014). In addition, Gli1 
upregulates SHh expression, which is secreted from and acts on 
stromal cells, able to respond to SHh, enhancing Foxf1 and Foxf2 
expression, which inhibit mesenchymal expression of Wnt5a and 
lead to suppression of β-catenin (Ormestad et al., 2006).
A controversial communication between Hh and Wnt 
signaling is highlighted in MB. In fact, on one hand, it is 
reported that SuFu is able to bind β-catenin and to export it from 
the nucleus and thereby to repress β-catenin/TCF–mediated 
transcription. Loss of SuFu function not only is associated 
with an increased risk of MB but also results in over-activity 
of both SHh and Wnt signaling pathways (Taylor et al., 2004). 
On the other hand, the activation of Wnt/β-catenin signaling 
specifically decreases the proliferation of SHh-dependent 
cerebellar granule cell precursors (GCPs) (Poschl et  al., 
2014) and of SHh-MB cells, by inducing Gli to proteosomal 
degradation upon a direct interaction between β-catenin and 
Gli proteins (Zinke et al., 2015).
Of interest is the demonstration that the mutations in Wnt 
signaling are recently described in about 15% of MB, corresponding 
to a minority, and defining a subset of patients with improved 
outcomes (Swartling et al., 2010). Nevertheless, N-Myc, a known 
target gene of the Wnt pathway, is also related to a subtype group 
of MB (Kool et al., 2008), suggesting its important role in the MB 
pathogenesis. Moreover, several groups report that SHh promotes 
the expression and post-transcriptional stabilization of N-Myc in 
mice (Kenney et al., 2003, Thomas et al., 2009).
To date, loss-of-function and gain-of-function mutations 
in known regulators of the Hh signaling pathway have been 
elucidated in hematological malignancies (Campbell and 
Copland, 2015), and the involvement of an autocrine and/or 
paracrine Hh signaling has been also demonstrated in multiple 
myeloma (Blotta et al., 2012), lymphoma (Dierks et al., 2007), 
and colon cancers (Bian et al., 2007; Yoshikawa et  al., 2009). 
Genetic and epigenetic mutations in Wnt signaling components 
are also identified in leukemia (Staal et al., 2016). Intriguingly, 
the ability of Hh to crosstalk with Wnt is suggested by 
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Sengupta and coworkers, who demonstrated that Hh signaling 
via Stat3 activation gives rise to the expression of Wnt3a, Lef1, 
Gli1–3, and other target genes in the chronic phase of chronic 
myeloid leukemia (CML) (Sengupta et al., 2007). Although it 
has been reported that the Hh inhibitor cyclopamine and the 
WNT inhibitor quercitin suppress the growth of leukemia cells 
(Kawahara et al., 2009), direct crosstalk between Hedgehog 
and Wnt/β-catenin in hematological disorders has not yet been 
well evaluated (Figure 2).
Crosstalk Between Hh and TGF-β 
Signaling Pathways
Mammalian TGF-β family members include more than 35 
structurally related secreted proteins, including TGF-βs stricto sensu, 
bone morphogenetic proteins (BMPs), growth differentiation 
factors (GDFs), glial-derived neurotrophic factors (GDNFs), 
Nodal, Lefty, and the Müllerian inhibitory substance/anti-
Müllerian hormone (MIS/AMH) (Zi et al., 2012). Members of 
the TGF-β family play fundamental roles during embryonic 
development and in maintenance of tissue homeostasis since 
they regulate diverse cellular processes, such as proliferation, 
differentiation, migration, and extracellular matrix synthesis 
(Verrecchia and Mauviel, 2007).
Family members of TGF-β stricto sensu are identified in three 
isoforms: TGF-β1, TGF-β2, and TGF-β3. They signal via cell-
surface receptors, which consist of specific hetero-oligomeric 
complex of type-I and type-II serine/threonine kinase receptors 
(TbR-I and TbR-II). Typically, TGF-β signaling initiates with 
the binding to and subsequently activation of TbR-I and TbR-II. 
Smad proteins are the initial responders and transduce the signal 
from the TGF-β receptor activation process. Smads comprise a 
family of structurally similar proteins with different functions: 
receptor-regulated (R-Smads), common mediator (Co-Smads), 
and inhibitory (I-Smads). After ligand binding, the TbR-II 
receptor phosphorylates TbR-I, which in turn phosphorylates and 
activates R-Smads (e.g., Smad2 and Smad3). Then, the R-Smads 
bind to Co-Smads (e.g., Smad4), and this complex translocates 
to the nucleus, where it regulates the transcription of TGF-β–
responsive genes, involved in cytostatic and/or apoptotic events 
(p15 and p21) (Pardali et al., 2000; Seoane et al., 2001; Siegel 
and Massague, 2003), proliferation (c-Myc) (Chen et al., 2002), 
and the transcription of elements of other signaling pathways, 
such as Hes1 and Jagged1 (Zavadil et al., 2004). On the contrary, 
the I-Smads exert a negative feedback effect by competing 
with R-Smads for interaction with the receptor. Therefore, the 
I-Smads (e.g., Smad7) associate with ligand–TbR-I receptor 
complex and interfere with phosphorylation of R-Smads (e.g., 
Smad3), by preventing their interaction with activated TbR-I. 
Since the expression of Smad7 is induced by TGF-β1, in turn, it 
inhibits TGF-β signaling by a negative feedback system (Wahl, 
1994, Moustakas et al., 2001). Several publications display a 
crosstalk between TGF-β and Hh signaling pathways in cancer 
(Figure 2). In the onset of BCC, GLI2 is identified as an early 
target gene of the TGF-β/SMAD cascade, independently by 
Hedgehog signaling activity (Dennler et al., 2007). Interestingly, 
Gli1 is induced by TGF-β in a Gli2-dependent manner, and 
such an induction is not inhibited by cyclopamine, an SMO 
antagonist, demonstrating that Hh signaling is not required 
(Dennler et al., 2007). Concomitantly, studies show that TGF-β 
inhibits PKA activity, which may contribute to increasing the 
pool of Gli activator proteins (Pierrat et al., 2012). In addition, 
Hh signaling induced the expression of TGF-β members. In 
detail, in the mouse model of SMO-mediated BCC, Fan and 
colleagues identify TGF-β2 as an Hh target gene (Fan et al., 
2010). Thus, the crosstalk between Hh and TGF-β may activate 
a vicious circuitry, able to promote and amplify downstream 
targets of Gli1/2, which in turn sustains the activation of TGF-β 
and Hh itself (Figure 2).
During the development of the cerebellum, the GCPs 
express BMPs. It is reported that in GCPs, BMP‐2 and ‐4 
antagonize the proliferative effects of Hh through SMAD5. In 
addition, BMPs downregulate Hh signaling proteins such as 
SMO and Gli1. Moreover, it is suggested that BMP‐2 inhibits 
proliferation and promotes cell differentiation of GCPs, by 
downregulating the oncogene N-Myc (Alvarez-Rodriguez 
et al., 2007).
It is well described that the architectural structure of 
the colon is controlled by a gradient of WNT, Hh, BMP, and 
Notch signaling (Geissler and Zach, 2012). In particular, BMP 
signaling exerts its function in the differentiated compartment 
at the top of the crypt, while it is relatively inactive in early 
compartments at the bottom of the crypt, due to the presence of 
the BMP inhibitor, Noggin (Syed, 2016). Thus, the Hh and BMP 
overlapping signaling pathways in the crypt regulate stem cell 
self-renewal, proliferation, and differentiation, but the existence 
of a direct regulation between them is not defined yet. However, 
loss of phosphorylation of Smad1, Smad5, and Smad8 is 
observed in 70% of sporadic colon cancer (Kodach et al., 2008). 
Loss of Smad4 or BMPRII function is the likely mechanistic 
basis for inactivated BMP signaling in sporadic colon cancer. 
In fact, several reports support the hypothesis that TGF-β/BMP 
signaling is involved in invasion/metastasis events in tumor cells 
(Zavadil and Bottinger, 2005).
Although TGF-β is proposed to be a potent negative 
regulator of hematopoiesis (Fortunel et al., 2000; Fortunel 
et  al., 2003) and the loss of TGF-β signaling is reported in 
several leukemias (Le  Bousse-Kerdiles et al., 1996; DeCoteau 
et al., 1997; Jakubowiak et al., 2000; Imai et al., 2001; Wolfraim 
et al., 2004), the disruption of TGF-β signaling alone is not 
sufficient to induce leukemia (Datto et al., 1999, Yang et al., 
1999; Larsson et al., 2003). Thus, its role in leukemogenesis and 
its ability to crosstalk with other signaling pathways remain 
largely unknown.
CONCLUSION
Biological processes such as stem cell self-renewal, cell growth, 
and differentiation are orchestrated by a number of major 
signaling pathways that integrate with each other to modulate 
cell outcomes in response to several intracellular signals.
The picture in Figure 2 schematically summarizes the intricate 
molecular crosstalk between Hh, Notch, Wnt,  and  TGF-β, 
Hh Signaling at a CrossroadPelullo et al.
9 August 2019 | Volume 10 | Article 711Frontiers in Genetics | www.frontiersin.org
which  establishes a network of protein–protein interactions 
able to affect gene expression programs across the pathways. 
The cartoon clearly represents the complexity of molecular 
interlinking inside the tumor cell, which is underlying the 
severity of the neoplasia phenomenon. The pathogenesis of 
malignancies is characterized by dysregulation of at least two 
pathways at the same time, proving a functional advantage to 
neoplastic cells, influencing relapse and drug responsiveness. 
We need to unravel the intricate signaling networks between the 
major pathways to prevent tumor formation and/or to contribute 
to the development of novel anticancer treatment modalities. 
Aberrant activation of the Hh pathway is tightly associated 
with cancer development. Notably, a plethora of stimuli activate 
multiple signaling cascades in tumor cells, which can impinge 
on Hh signaling and affect its output, by direct protein–protein 
interaction or by regulating indirectly the expression of key 
TABLE 1 | Mutations of HH signaling
Gene Locus Disease Inheritance Mutations Reference
Loss of function
Ptch1 9q22.32
Gorlin syndrome Germline Insertion deletion Hahn et al., 1996; Lindstrom et al., 2006
Rhabdomyosarcoma Germline Missense Bridge et al., 2000;
Taeubner et al., 2018
Medulloblastoma Germline Somatic Insertion Deletion 
Frameshift LOH
Raffel et al., 1997; Reifenberger et al., 
1998; Zurawel et al., 2000; Thompson 
et al., 2006; Kool et al., 2014; Rusert 
et al., 2014
Basal cell carcinoma Somatic Missense LOH Gailani et al., 1996;
Reifenberger et al., 2005
Leukemia Germline Somatic Missense Dagklis et al., 2015; Burns et al., 2018
Breast cancer NA LOH Naylor et al., 2005; Wood et al., 2007; 
Sinha et al., 2008
Gastric–intestinal 
cancer
NA Frameshift Missense Wang et al., 2013
Gorlin syndrome Germline Missense Frameshift Fan and Eberhart, 2008; Fujii et al., 2013
Ptch2 1p34.1
Rhabdomyosarcoma Germline Missense Taeubner et al., 2018
Leukemia NA Transition Dagklis et al., 2015
SuFu 10q24.32
Gorlin syndrome Germline Nonsense Missense 
deletion
Smith et al., 2014
Rhabdomyosarcoma Germline LOH Bridge et al., 2000
Medulloblastoma Germline Somatic Missense deletion 
Truncating LOH
Taylor et al., 2002; Thompson et al., 
2006; Rusert et al., 2014; Kool et al., 
2014
Leukemia Somatic Missense Burns et al., 2018
Basal cell carcinoma Somatic Missense Reifenberger et al., 2005
Prostate cancer Somatic LOH deletion 
Nonsense
Sheng et al., 2004
Meningioma Germline Missense LOH Aavikko et al., 2012
Gli3 7p14.1
Pancreatic cancer Somatic Missense Jones et al., 2008
Leukemia Germline Somatic Missense Dagklis et al., 2015; Burns et al., 2018
Colorectal cancer NA Missense Wood et al., 2007
Gain of function
Gli1 12q13.3
Rhabdomyosarcoma Germline Amplification Roberts et al., 1989
Medulloblastoma Somatic Amplification Thompson et al., 2006; Northcott et al., 
2009
Leukemia Somatic Missense Dagklis et al., 2015; Burns et al., 2018
Breast cancer Somatic Amplification Nessling et al., 2005; Wood et al., 2007; 
Jiao et al., 2012
Pancreatic cancer Somatic Missense Jones et al., 2008
Colorectal cancer Somatic Frameshift Lee et al., 2018
Gli2 2q14.2
Medulloblastoma Somatic Amplification Northcott et al., 2009; Rusert et al., 2014; 
Kool et al., 2014
Leukemia Somatic Missense Burns et al., 2018;
SMO 7q32.1
Medulloblastoma Somatic Missense Reifenberger et al., 1998; Rusert et al., 
2014; Kool et al., 2014
Basal cell carcinoma Somatic Missense Reifenberger et al., 1998; Reifenberger 
et al., 2005
Leukemia Somatic Frameshift Dagklis et al., 2015
Gastric–intestinal 
cancer
NA Missense Insertion Wang et al., 2013
Ameloblastoma Somatic Missense Sweeney et al., 2014
SHH 7q36.3
Medulloblastoma NA Amplification Reifenberger et al., 1998; Kool et al., 2014
Basal cell carcinoma Somatic Missense Couve-Privat et al., 2004
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components of the signaling. Conversely, the Hh pathway 
can also have an impact on other pathways, determining a 
mutual signaling interference, a phenomenon underlying an 
unbalanced network in cancer cells. The Hh signaling pathway 
is considered an important molecular cross point able to 
integrate/synergize with other major signaling cascades, such 
as Wnt, TGF-β, and Notch. Therefore, Figure 2 presents an 
overview concerning direct or indirect molecular mechanisms 
that sustain Hh cross-talking with major signaling pathways. 
Molecular sharing between Hh and the Wnt/β-catenin, Notch, 
or TGF-β signaling pathway suggests that two major signaling 
networks crosstalk with each other during oncogenesis. 
Therefore, a combined involvement of these signaling pathways 
in early stages of tumorigenesis as well as in the metastatic 
process in several types of cancers suggests the need to combine 
novel targeted inhibitors with standard antineoplastic therapy to 
enhance therapy efficacy.
This complex scenario could open a huge window of 
opportunity for the development of new therapeutic drugs for 
multiple cancers.
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